<DOC>
	<DOCNO>NCT00281892</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , fludarabine , work different way stop growth cancer cell , either kill cell stop dividing . Darbepoetin alfa may cause body make red blood cell . It yet know whether fludarabine effective without darbepoetin alfa treat chronic lymphocytic leukemia . PURPOSE : This phase III trial study fludarabine see well work give together without darbepoetin alfa treat old patient chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Fludarabine Darbepoetin Alfa Treating Older Patients With Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy fludarabine without darbepoetin alfa geriatric patient chronic lymphocytic leukemia relevant comorbidities . - Determine effect regimens reduce anemia , lower requirement transfusion , reduce duration frequency hospitalization patient . - Determine quality life patient treat regimen . - Determine event-free , progression-free , overall survival patient treat regimen . - Evaluate medical-economical aspect regimens patient OUTLINE : This multicenter study . Patients stratify accord hemoglobin value ( &lt; 12 g/dL [ stratum 1 ] v &gt; 12 g/dL [ stratum 2 ] ) . Patients assign 1 2 treatment stratum . - Stratum 1 : Patients receive fludarabine IV day 1 , 3 , 5 . Treatment repeat every 28 day 6 course . Patients also receive darbepoetin alfa subcutaneously weekly 6 week . - Stratum 2 : Patients receive fludarabine stratum 1 . Quality life evaluate periodically . PROJECTED ACCRUAL : A total 348 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis chronic lymphocytic leukemia ( CLL ) meet 1 follow criterion : Previously untreated disease Progressive relapse CLL treatment nonpurine analogcontaining regimen chlorambucil bendamustine hydrochloride Meets 1 follow stag criterion : Binet stage A disease B symptoms require treatment Binet stage B disease require treatment , meet â‰¥ 1 follow criterion : Rapid disease progression Enlarged lymph node organ Severe B symptom Binet stage C disease Must comorbidities ( i.e. , CIRS score &gt; 6 ) Must restrict kidney function ( i.e. , creatinine clearance &lt; 70mL/min ) No transformation aggressive nonHodgkin 's lymphoma ( Richter 's syndrome ) PATIENT CHARACTERISTICS : Life expectancy &gt; 6 month Creatinine clearance &gt; 30 mL/min No active second malignancy No active bacterial , viral , fungal infection No condition would preclude substitution iron No severe myocardial , coronary , respiratory insufficiency No severe liver insufficiency No known hypersensitivity darbepoetin alfa No cerebral dysfunction would preclude participation require study procedure PRIOR CONCURRENT THERAPY : See Disease Characteristics No concurrent participation another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>anemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>stage 0 chronic lymphocytic leukemia</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
</DOC>